Sarcopenia

Authors

  • Oriana Franceschinis Argentine Diabetes Society, City of Buenos Aires, Argentina

Keywords:

sarcopenia, diabetes

Abstract

Skeletal muscle is the primary endocrine and metabolic organ responsible for approximately 80% of insulin-mediated postprandial glucose clearance1. Consequently, the loss of muscle mass and function (sarcopenia), exacerbated by central obesity, acts as an early, bidirectional pathogenic driver in the transition from prediabetes to type 2 diabetes mellitus (T2DM). Visceral adipose tissue dysfunction promotes ectopic intramuscular lipid accumulation (myosteatosis) and the subsequent build-up of diacylglycerols and ceramides. These lipotoxic mediators disrupt the insulin receptor substrate-1 (IRS-1/PI3K/Akt) signaling cascade, preventing GLUT4 transporter translocation to the cell membrane. This process drives metabolic inflexibility, impairing mitochondrial capacity to efficiently switch between glucose and fatty acid oxidation1.

Concurrently, subclinical hyperglycemia exerts a direct glucotoxic effect on muscle tissue. A critical HbA1c inflection point at 5.2% has recently been identified in non-diabetic individuals; above this threshold, appendicular muscle mass loss accelerates significantly through the activation of proteolytic pathways, such as the ubiquitin-proteasome system via the WWP1/KLF15 axis2.

In clinical practice, diagnosing sarcopenic obesity requires a systematic, sequential approach based on the ESPEN/EASO international consensus, prioritizing muscle strength assessment (handgrip strength) followed by body composition confirmation (appendicular skeletal muscle mass normalized by weight using DXA or BIA)3,4.

Finally, in the current era of incretin-based therapies (GLP-1 receptor agonists and GIP/GLP-1 co-agonists), clinical management of obesity faces a crucial challenge: mitigating lean mass loss, which can account for 25% to over 40% of total weight loss. To ensure "high-quality weight loss," preserve resting energy expenditure, and restore insulin sensitivity, it is mandatory to prescribe progressive resistance training and guarantee an optimized protein intake of 1.2 to 1.6 g/kg/day.

Author Biography

Oriana Franceschinis, Argentine Diabetes Society, City of Buenos Aires, Argentina

Medical specialist in Internal Medicine and Nutrition, specializing in Diabetes, member of the Argentine Diabetes Society

References

I. Mengeste AM, Rustan AC, Lund J. Skeletal muscle energy metabolism in obesity. Obesity (Silver Spring). 2021;29(8):1227-1237.

II. Li S, Mao J, Zhou W. Prediabetes is associated with loss of appendicular skeletal muscle mass and sarcopenia. Front Nutr. 2023;10:1109824.

III. Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321-335.

IV. Habboub B, Speer R, Gosch M, Singler K. The diagnosis and treatment of sarcopenia and sarcopenic obesity. Dtsch Arztebl Int. 2025;122(1-2):1-10.

Published

2026-10-01